Quince Therapeutics sells A-T assets to Ayma for $450K; President Ryan departs

Quince Therapeutics, Inc.

Completed sale of Quince SpA, AIDE IP, and eDSP machines to Ayma Therapeutics for $450,000 cash on Sept 8, 2026.
Sale includes ~55 AIDE/eDSP machines: ~20 at Italian facilities, ~35 at clinical trial sites.
President Charles Ryan separated Sept 8, 2026; severance of $1,014,489.04 under Separation Agreement.
Pro forma financials assume sale effective Jan 1, 2025 for operations; balance sheet as of June 30, 2026.

Featured in Daily 8-K Digest

Selected #1 for 2026-09-14. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.